Adds details on injection intervals, expected approval timing, shares
May 23 (Reuters) - German drugmaker Bayer BAYGn.DE on Friday won an endorsement by the European Medicines Agency to extend the intervals between shots of its anti-blindness treatment Eylea, giving it a potential edge over Roche's ROG.S rival treatment Vabysmo.
Bayer said in a statement the European Medicines Agency recommended that eye drug Eylea, at a high dose of 8 mg, can be injected at intervals of up to six months to treat wet age-related macular degeneration and diabetic macular oedema.
Bayer shares were up 2.5% at 0717 GMT, surpassing a gain of 0.7% in the Stoxx Europe 600 Health Care index.
Eylea, an injection against the leading causes of blindness among the elderly, is currently approved in the EU for treatment intervals of up to five months. Bayer has developed it jointly with Regeneron REGN.O.
Vabysmo, a major driver of revenue growth for Switzerland's Roche, is cleared to be given at intervals of up to four months.
The EU commission has the final say on drug approval but it typically follows the medicines agency's opinions. Bayer said that decision is expected within the next few weeks.
(Reporting by Ludwig Burger, Editing by Friederike Heine)
((ludwig.burger@thomsonreuters.com;))
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。